獸醫自體免疫疾病治療市場機會、成長動力、產業趨勢分析及 2025 - 2034 年預測

2024 年全球獸醫自體免疫疾病治療市場價值為 35 億美元，預計到 2034 年將以 6.3% 的複合年成長率成長至 64 億美元。

動物自體免疫疾病發生率的上升，以及寵物飼養趨勢的日益成長，持續推動了對有效獸醫治療的需求。隨著人們對動物健康意識的提升、診斷技術的進步以及對寵物長期健康需求的增加，市場正在獲得顯著成長。治療方法正在不斷發展，以應對動物免疫系統針對自身組織的複雜疾病。這推動了生物製劑、免疫抑制藥物和個人化治療等領域的創新，有助於提高疾病管理的準確性和療效。

目前，針對自體免疫疾病的獸醫療法種類繁多，從皮質類固醇到先進的生物製劑，有助於更有效地控制狼瘡、天皰瘡和免疫介導性貧血等疾病。市場正在見證藥物傳輸系統的重大技術進步，從而提高依從性和治療效果。各公司正在優先考慮生態環保的療法，包括有機和永續的藥物配方。獸藥製造商與學術研究機構之間的密切合作正在加速獲得更新、更有針對性的療法。長效注射劑和定製藥物日益受到關注，這有助於改善多種動物的治療效果和生活品質。

2024年，皮質類固醇市場規模達12億美元。這一市場主導地位源自於其快速起效、成本效益高，以及對多種動物自體免疫疾病的療效已得到證實。這些藥物常用於透過調節發炎和免疫反應來控制與免疫相關疾病相關的症狀，例如免疫介導性關節炎、甲狀腺功能減退症和貧血。皮質類固醇的可及性和已證實的有效性使其成為全球獸醫治療慢性和急性病例的基石。

甲狀腺功能減退症在2024年佔據30.6%的市場佔有率，成為領先的疾病適應症。甲狀腺功能減退症是犬類最常見的自體免疫疾病之一，由於免疫系統功能障礙導致甲狀腺激素分泌減少。甲狀腺功能減退症的高發性促使人們開發針對該疾病的藥物，以恢復伴侶動物的荷爾蒙平衡並改善其整體健康狀況。寵物疲勞、脫髮和肥胖等主要症狀正擴大透過持續精準的荷爾蒙替代療法得到控制。

2024年，美國獸醫自體免疫疾病治療市場規模達13.5億美元。寵物和牲畜免疫疾病的發生率不斷上升，推動了對免疫抑制劑等治療藥物以及幹細胞干預等新型療法的需求。美國市場受惠於強大的研發實力，並在獸藥公司與國家機構的合作支持下，持續提升產品的安全性和有效性。對先進診斷技術的投資不斷增加以及獲得尖端獸醫護理服務的管道不斷拓寬，也促進了該地區的成長。

積極影響全球獸醫自體免疫疾病治療市場的主要公司包括碩騰 (Zoetis)、詩華 (Ceva Sante Animale)、Vet-Stem、Aratana Therapeutics、瑪氏獸醫 (Mars Veterinary Health)、Dechra Pharmaceuticals、諾布魯克 (Norbrook)、Vequinol、赫斯卡來 (Heskaan) 和梅卡來為了鞏固市場地位，獸醫自體免疫疾病治療市場的公司正在推行各種策略性舉措，包括擴大地域覆蓋範圍，進入寵物擁有量和牲畜護理需求不斷成長的尚未普及的地區。許多公司正在大力投資研發，以開發針對伴侶動物的標靶生物製劑、單株抗體和個人化醫療方案。與研究機構和獸醫診所的合作可以加快新療法的開發和批准速度。

目錄

第1章：方法論與範圍

第 2 章：執行摘要

第3章：行業洞察

• 產業生態系統分析
  • 供應商格局
  • 每個階段的增值
  • 影響價值鏈的因素
• 產業衝擊力
  • 成長動力
    • 人畜共通傳染病在人與人之間傳播的威脅日益增加
    • 牲畜自體免疫疾病發生率上升
    • 提高對自體免疫疾病的認知與診斷
    • 伴侶動物飼養量不斷增加
    • 增加動物保健支出
  • 產業陷阱與挑戰
    • 獸醫自體免疫療法成本高昂
    • 自體免疫藥物增加感染風險
  • 市場機會
    • 對特定品種和個人化治療的需求不斷成長
    • 遠距醫療和遠距獸醫診斷的成長
• 成長潛力分析
• 監管格局
  • 北美洲
  • 歐洲
  • 亞太地區
• 未來市場趨勢
• 技術格局
  • 目前技術
  • 新興技術
• 定價分析
• 差距分析
• 波特的分析
• PESTEL分析

第4章：競爭格局

• 介紹
• 公司市佔率分析
  • 全球的
  • 北美洲
  • 歐洲
• 公司矩陣分析
• 主要市場參與者的競爭分析
• 競爭定位矩陣
• 關鍵進展
  • 併購
  • 夥伴關係與協作
  • 新產品發布
  • 擴張計劃

第5章：市場估計與預測：按治療類型，2021 - 2034 年

• 主要趨勢
• 皮質類固醇
• 硫唑嘌呤
• 環孢菌素
• 黴酚酸酯
• 來氟米特
• 環磷醯胺
• 左甲狀腺素
• 其他治療類型

第6章：市場估計與預測：按疾病，2021 - 2034 年

• 主要趨勢
• 甲狀腺功能低下症
• 天皰瘡疾病
• 犬狼瘡
• 自體免疫性溶血性貧血
• 大疱性類天疱瘡
• 盤狀紅斑狼瘡（DLE）
• 免疫相關關節炎
• 其他疾病

第7章：市場估計與預測：按動物類型，2021 - 2034 年

• 主要趨勢
• 伴侶動物
  • 狗
  • 貓
  • 馬匹
  • 其他伴侶動物
• 牲畜
  • 牛
  • 豬
  • 家禽
  • 羊
  • 其他牲畜
• 其他動物

第 8 章：市場估計與預測：按管理路線，2021 年至 2034 年

• 主要趨勢
• 口服
• 注射劑
• 外用

第9章：市場估計與預測：按配銷通路，2021 - 2034 年

• 主要趨勢
• 獸醫院
• 獸醫診所
• 其他分銷管道

第 10 章：市場估計與預測：按地區，2021 年至 2034 年

• 主要趨勢
• 北美洲
  • 美國
  • 加拿大
• 歐洲
  • 德國
  • 英國
  • 法國
  • 西班牙
  • 義大利
  • 荷蘭
• 亞太地區
  • 中國
  • 印度
  • 日本
  • 澳洲
  • 韓國
• 拉丁美洲
  • 巴西
  • 墨西哥
  • 阿根廷
• 中東和非洲
  • 南非
  • 沙烏地阿拉伯
  • 阿拉伯聯合大公國

第 11 章：公司簡介

• Aratana Therapeutics
• Ceva Sante Animale
• Dechra Pharmaceuticals
• Elanco
• Heska
• Mars Veterinary Health
• Merck
• Norbrook
• Vetoquinol
• Vet-Stem
• Virbac
• Zoetis

The Global Veterinary Autoimmune Disease Therapeutics Market was valued at USD 3.5 billion in 2024 and is estimated to grow at a CAGR of 6.3% to reach USD 6.4 billion by 2034.

The rising occurrence of autoimmune disorders in animals, along with the growing trend of pet ownership, continues to fuel the demand for effective veterinary treatments. With increased awareness around animal health, diagnostic advancements, and demand for long-term wellness in pets, the market is gaining significant traction. Treatments are evolving to address complex conditions where an animal's immune system targets its own tissues. This has driven innovation in areas such as biologics, immunosuppressive drugs, and personalized therapeutics, helping boost both accuracy and outcomes in disease management.

Veterinary therapies designed for autoimmune diseases now range from corticosteroids to advanced biologic solutions, helping to manage conditions like lupus, pemphigus, and immune-mediated anemia more effectively. The market is witnessing major technological progress in drug delivery systems, resulting in improved adherence and treatment efficacy. Companies are prioritizing eco-conscious therapies, including organic and sustainable drug formulations. Strong collaboration between veterinary pharmaceutical manufacturers and academic research bodies is accelerating access to newer, more targeted therapeutics. A growing focus on long-acting injectables and tailored medications is helping improve both treatment outcomes and quality of life for affected animals across multiple species.

The corticosteroids segment reached USD 1.2 billion in 2024. This dominance stems from their quick therapeutic impact, cost-effectiveness, and proven efficacy across a wide range of autoimmune disorders in animals. These drugs are frequently used to manage symptoms linked with immune-related conditions such as immune-mediated arthritis, hypothyroidism, and anemia by modulating inflammation and the immune response. Their accessibility and established effectiveness make corticosteroids a cornerstone treatment option for veterinarians worldwide in managing chronic and acute cases.

The hypothyroidism segment held a 30.6% share in 2024, making it the leading disease indication. This condition is one of the most common autoimmune disorders diagnosed in dogs, leading to reduced production of thyroid hormones due to immune system malfunction. The high occurrence of hypothyroidism has led to the development of disease-specific drugs that restore hormonal balance and improve overall health in companion animals. Key symptoms such as fatigue, hair loss, and obesity in pets are increasingly being managed through consistent and precise hormone replacement therapies.

U.S Veterinary Autoimmune Disease Therapeutics Market reached USD 1.35 billion in 2024. The rising prevalence of immune disorders in both pets and livestock is driving demand for treatments such as immunosuppressants and newer modalities like stem cell-based interventions. The U.S. market benefits from a robust pipeline of research efforts, supported by collaborations between veterinary pharmaceutical companies and national institutions, which continue to enhance product safety and efficacy. Increasing investments in advanced diagnostics and access to cutting-edge veterinary care are also contributing to regional growth.

Major companies actively shaping the Global Veterinary Autoimmune Disease Therapeutics Market include Zoetis, Ceva Sante Animale, Vet-Stem, Aratana Therapeutics, Mars Veterinary Health, Dechra Pharmaceuticals, Norbrook, Vetoquinol, Heska, Elanco, Merck, and Virbac. To strengthen their foothold, companies in the Veterinary Autoimmune Disease Therapeutics Market are pursuing a variety of strategic initiatives. These include expanding their geographical reach to enter underpenetrated regions with rising pet ownership and livestock care needs. Many firms are investing heavily in R&D to develop targeted biologics, monoclonal antibodies, and personalized medicine options for companion animals. Collaborations with research organizations and veterinary clinics enable faster development and approval of novel therapies.

Table of Contents

Chapter 1 Methodology and Scope

• 1.1 Market scope and definition
• 1.2 Research design
  • 1.2.1 Research approach
  • 1.2.2 Data collection methods
• 1.3 Data mining sources
  • 1.3.1 Global
  • 1.3.2 Regional/country
• 1.4 Base estimates and calculations
  • 1.4.1 Base year calculation
  • 1.4.2 Key trends for market estimation
• 1.5 Primary research and validation
  • 1.5.1 Primary sources
• 1.6 Forecast model
• 1.7 Research assumptions and limitations

Chapter 2 Executive Summary

• 2.1 Industry 360° synopsis
• 2.2 Key market trends
  • 2.2.1 Regional
  • 2.2.2 Therapy type
  • 2.2.3 Disease
  • 2.2.4 Animal type
  • 2.2.5 Route of administration
  • 2.2.6 Distribution channel
• 2.3 CXO perspectives: Strategic imperatives
  • 2.3.1 Key decision points for industry executives
  • 2.3.2 Critical success factors for market players
• 2.4 Future outlook and strategic recommendations

Chapter 3 Industry Insights

• 3.1 Industry ecosystem analysis
  • 3.1.1 Supplier landscape
  • 3.1.2 Value addition at each stage
  • 3.1.3 Factor affecting the value chain
• 3.2 Industry impact forces
  • 3.2.1 Growth drivers
    • 3.2.1.1 Increasing threat of transfer of zoonotic diseases among humans
    • 3.2.1.2 Rising incidence of auto-immune diseases in livestock animals
    • 3.2.1.3 Increasing awareness and diagnosis of autoimmune diseases
    • 3.2.1.4 Growing companion animal ownership
    • 3.2.1.5 Increasing expenditure on animal healthcare
  • 3.2.2 Industry pitfalls and challenges
    • 3.2.2.1 High cost of veterinary autoimmune therapies
    • 3.2.2.2 Increased risk of infection due to autoimmune drugs
  • 3.2.3 Market opportunities
    • 3.2.3.1 Rising demand for breed-specific and personalized treatments
    • 3.2.3.2 Growth in telemedicine and remote veterinary diagnostics
• 3.3 Growth potential analysis
• 3.4 Regulatory landscape
  • 3.4.1 North America
  • 3.4.2 Europe
  • 3.4.3 Asia Pacific
• 3.5 Future market trends
• 3.6 Technology landscape
  • 3.6.1 Current technology
  • 3.6.2 Emerging technologies
• 3.7 Pricing analysis
• 3.8 Gap analysis
• 3.9 Porter’s analysis
• 3.10 PESTEL analysis

Chapter 4 Competitive Landscape, 2024

• 4.1 Introduction
• 4.2 Company market share analysis
  • 4.2.1 Global
  • 4.2.2 North America
  • 4.2.3 Europe
• 4.3 Company matrix analysis
• 4.4 Competitive analysis of major market players
• 4.5 Competitive positioning matrix
• 4.6 Key developments
  • 4.6.1 Merger and acquisition
  • 4.6.2 Partnership and collaboration
  • 4.6.3 New product launches
  • 4.6.4 Expansion plans

Chapter 5 Market Estimates and Forecast, By Therapy Type, 2021 - 2034 ($ Mn)

• 5.1 Key trends
• 5.2 Corticosteroids
• 5.3 Azathioprine
• 5.4 Cyclosporine
• 5.5 Mycophenolate
• 5.6 Leflunomide
• 5.7 Cyclophosphamide
• 5.8 Levothyroxine
• 5.9 Other therapy types

Chapter 6 Market Estimates and Forecast, By Disease, 2021 - 2034 ($ Mn)

• 6.1 Key trends
• 6.2 Hypothyroidism
• 6.3 Pemphigus disease
• 6.4 Canine lupus
• 6.5 Auto-immune haemolytic anaemia
• 6.6 Bullous pemphigoid
• 6.7 Discoid lupus erythematosus (DLE)
• 6.8 Immune-related arthritis
• 6.9 Other diseases

Chapter 7 Market Estimates and Forecast, By Animal Type, 2021 - 2034 ($ Mn)

• 7.1 Key trends
• 7.2 Companion animals
  • 7.2.1 Dogs
  • 7.2.2 Cats
  • 7.2.3 Horses
  • 7.2.4 Other companion animals
• 7.3 Livestock animals
  • 7.3.1 Cattle
  • 7.3.2 Swine
  • 7.3.3 Poultry
  • 7.3.4 Sheep
  • 7.3.5 Other livestock animals
• 7.4 Other animals

Chapter 8 Market Estimates and Forecast, By Route of Administration, 2021 - 2034 ($ Mn)

• 8.1 Key trends
• 8.2 Oral
• 8.3 Injectable
• 8.4 Topical

Chapter 9 Market Estimates and Forecast, By Distribution Channel, 2021 - 2034 ($ Mn)

• 9.1 Key trends
• 9.2 Veterinary hospitals
• 9.3 Veterinary clinics
• 9.4 Other distribution channels

Chapter 10 Market Estimates and Forecast, By Region, 2021 - 2034 ($ Mn)

• 10.1 Key trends
• 10.2 North America
  • 10.2.1 U.S.
  • 10.2.2 Canada
• 10.3 Europe
  • 10.3.1 Germany
  • 10.3.2 UK
  • 10.3.3 France
  • 10.3.4 Spain
  • 10.3.5 Italy
  • 10.3.6 Netherlands
• 10.4 Asia Pacific
  • 10.4.1 China
  • 10.4.2 India
  • 10.4.3 Japan
  • 10.4.4 Australia
  • 10.4.5 South Korea
• 10.5 Latin America
  • 10.5.1 Brazil
  • 10.5.2 Mexico
  • 10.5.3 Argentina
• 10.6 Middle East and Africa
  • 10.6.1 South Africa
  • 10.6.2 Saudi Arabia
  • 10.6.3 UAE

Chapter 11 Company Profiles

• 11.1 Aratana Therapeutics
• 11.2 Ceva Sante Animale
• 11.3 Dechra Pharmaceuticals
• 11.4 Elanco
• 11.5 Heska
• 11.6 Mars Veterinary Health
• 11.7 Merck
• 11.8 Norbrook
• 11.9 Vetoquinol
• 11.10 Vet-Stem
• 11.11 Virbac
• 11.12 Zoetis